Sandoz TV Episode 18: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
Competing sustainably in biosimilars – more than just a numbers game
Holzkirchen, June 24, 2016
Following the Biosimilars Media Day in Schaftenau, Austria, Carol Lynch comments on what it will take to succeed in the global biosimilars market.
Sandoz announces plans for five major global biosimilar launches by 2020
Holzkirchen, June 20, 2016
Sandoz, a Novartis Division and the global leader in biosimilars, plans to launch five biosimilars of major oncology and immunology biologics across ...
New data demonstrates Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products
Holzkirchen, June 09, 2016
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies comparing its biosimilar etanercept and rituximab candidates with the originator products ...
Sandoz’ biosimilar rituximab regulatory submission accepted by European Medicines Agency
Holzkirchen, May 24, 2016
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche’s EU-licensed MabThera® (rituximab). Rituximab is a monoclonal antibody that is used ...
Ecuador earthquake recovery: Sandoz announces financial support and product donation
Holzkirchen, May 23, 2016
In the wake of the earthquake that devastated northwest Ecuador in April, Sandoz, a Novartis division, today announced that it will support the recovery effort with financial aid and a product donation.